3 min read
Measuring What Can't Be Seen: How PTSD Clinical Trials Prove a Drug Works
When an oncology drug is tested, the signal is often brutally clear. A tumor either shrinks on a scan or it does not. A...
Join Veristat and industry leaders in regulatory writing and submissions management to share and discuss the challenges of writing regulatory submissions in a continually changing regulatory environment. Regulatory submissions are becoming more complex and the guidelines, both US and global, regarding product data are more stringent than ever.
5th Annual Regulatory Writing for Product Approvals Conference
Dates: Wednesday, April 27- Thursday, April 28, 2016
Location: Wyndham Philadelphia Historic District 400 Arch Street, Philadelphia, PA 19016

EDITING CONSIDERATIONS FOR SUBMISSION DOCUMENTS
Discussion to be led by:
Paula Wun,
Senior Director, Medical Writing
Veristat
LEARNING OBJECTIVES
PANEL EXPERTS INCLUDE:
We hope to see you at this exciting panel discussion.
Veristat can offer you strategic guidance in planning for your regulatory submission, we provide representation at the agency meetings, and we provide the statistical as well as medical writing support to prepare the submission documents. We have over 20 years of experience helping clients prepare INDs, NDAs, BLAs, and MAAs.
Schedule a time to speak with Paula or any of Veristat’s experts at the show about the challenges you are trying to overcome with your current or upcoming submission project.
3 min read
Apr 27, 2026 Veristat Blog
When an oncology drug is tested, the signal is often brutally clear. A tumor either shrinks on a scan or it does not. A...
3 min read
Apr 24, 2026 Veristat Blog
In August 2024, the FDA declined to approve MDMA-assisted therapy for post-traumatic stress disorder. The decision...